TY - JOUR
TI - Impact of PD-L1 Protein Expression on Renal Cell Carcinoma
Histo-differentiation
AU - Tziakou, Paraskevi
AU - Theodoropoulos, Grigorios
AU - Tsiambas, Evangelos
AU - and Zizi-sermpetzoglou, Adamantia
AU - Peschos, Dimitrios and
AU - Mastronikoli, Sofianiki
AU - Thomopoulou, Georgia
AU - Thymara, Eirini and
AU - Kavantzas, Nikolaos
AU - Lazaris, Andreas C.
JO - ANTICANCER RESEARCH
PY - 2021
VL - 41
TODO - 8
SP - 3809-3813
PB - INT INST ANTICANCER RESEARCH
SN - 0250-1291
TODO - 10.21873/anticanres.15173
TODO - Renal; carcinoma; PD-L1; protein; immunotherapy; differentiation
TODO - Background/Aim: Renal cell carcinoma (RCC) comprises a variety of
pathological entities. Many RCCs are aggressive, demanding efficient
targeted and immune-therapeutic strategies. Programmed cell death
ligand-1 (PD-L1) is expressed mainly in hematopoietic cells and also in
epithelial cells. The aim of this study was to correlate PD-L1 protein
expression in a series of RCC tissues with their histo-pathological
features. Materials and Methods: One hundred (n=100) archival,
formalin-fixed and paraffin-embedded RCC tissue specimens were analysed
by immunohistochemistry. Conventional tumor proportion score (TPS)
qualitative assay was applied for evaluating protein expression levels.
Results: Based on the TPS evaluation, 8 (8%) cases were characterized
as positive, and the rest of them (n=92; 92%) as negative. A
progressive increase in PD-L1 positivity was significantly associated
with the differentiation grade of the examined malignancies (p=0.001).
Conclusion: Although PD-L1 over-expression is detected in low rates in
RCCs, its correlation with differentiation grade should be considered as
a factor for discriminating sub-groups of patients with specific
histo-pathological features eligible for targeted anti-PD-L1
immunotherapy strategies.
ER -